Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
U.S. FDA approves albumin-bound nanoparticle paclitaxel for breast cancer
February 10th, 2005
Thirty-eight US Oncology, Inc. affiliated medical centers nationwide continue to play a significant role in the clinical research of Abraxane that was approved by the U.S. Food and Drug Administration (FDA). Abraxane (paclitaxel protein-bound particles for injectable suspension), a next generation taxane, and the first in a new class of albumin-bound nanotechnology, was approved for the treatment of metastatic breast cancer. U.S. Oncology conducted a phase 2 clinical trial of Abraxane in patients with metastatic breast cancer who were resistant to taxane drugs and continue to participate in the ongoing clinical development of the drug. Clinical trials of Abraxane have...
Source: Women's Health Weekly (2005-02-10)
|
